{"id":900967,"date":"2025-10-28T07:58:00","date_gmt":"2025-10-28T11:58:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/"},"modified":"2025-10-28T07:58:00","modified_gmt":"2025-10-28T11:58:00","slug":"ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/","title":{"rendered":"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <b>AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalities<\/li>\n<li style=\"margin-bottom:6pt\">Includes immunotherapies and small molecule drugs targeting intracellular proteinopathies<\/li>\n<li style=\"margin-bottom:6pt\">Leadership in groundbreaking early-stage clinical trials reinforces Company\u2019s competencies\n<\/li>\n<\/ul>\n<p>\n        <b>Lausanne, Switzerland, October 28, 2025 &#8212; <\/b>AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia clinical trials, as Chairwoman of its Clinical Advisory Board (CAB).<\/p>\n<p>Prof. Mummery leads the cognitive disorders service at the UK\u2019s National Hospital for Neurology and Neurosurgery (NHNN), where she has practiced as a consultant neurologist since 2004. She is head of novel therapeutics at the Dementia Research Centre at University College London (UCL), and deputy director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to early phase trials in neurodegeneration.<\/p>\n<p>She has been senior investigator on more than 20 early-stage studies of disease-modifying agents in dementias, including the first-ever clinical trial of a gene silencing therapy targeting Tau to treat Alzheimer\u2019s disease, as well as trials of AC Immune\u2019s anti-pTau active immunotherapy candidate ACI-35.030 (JNJ-2056).<\/p>\n<p>\n        <b>Dr. Andrea Pfeifer, CEO of AC Immune SA, commented:<\/b> \u201cIt is a great honor that Prof. Mummery has accepted to lead our Clinical Advisory Board. As an investigator on the recently published Phase 1b\/2a trial of ACI-35.030 (JNJ-2056), Catherine has been instrumental in the progress we have achieved with our SupraAntigen<sup>\u00ae<\/sup> immunotherapies. This appointment will now extend her involvement across our entire pipeline of precision prevention candidates, including our three active immunotherapies in Phase 2 development and our most exciting novel therapeutics targeting intracellular mechanisms of neurodegenerative diseases that are approaching the clinic, including ACI-19764 targeting NLRP3, our Morphomer<sup>\u00ae<\/sup> Tau program, and our Morphomer<sup>\u00ae<\/sup> a-syn program.\u201d<\/p>\n<p>\n        <b>Prof. Catherine Mummery, Chair of AC Immune\u2019s Clinical Advisory Board, added:<\/b> \u201cAC Immune is a leader in the development of precision prevention approaches for neurodegenerative diseases, and I am excited by the opportunity to lead its Clinical Advisory Board. I am looking forward to working with and advising the Company\u2019s talented team as its pipeline of active immunotherapies nears meaningful inflection points in clinical trials, plus a series of first-in-class small molecules that enable intracellular targeting of pathologic proteins moving toward the clinic.\u201d<\/p>\n<p>The CAB provides AC Immune with strategic clinical development and regulatory advice and members are selected based on their expertise and peer recognition in the field of neurodegeneration.<\/p>\n<p>As well as Prof. Mummery, the CAB also includes: Dr. Reisa Sperling, Brigham and Women&#8217;s Hospital and Massachusetts General Hospital, Boston (US); Dr. Murat Emre, Istanbul Faculty of Medicine, Istanbul University, Istanbul (Turkey); Dr. Lon Schneider, Keck School of Medicine of University of Southern California, Los Angeles, CA (US); Dr. Pierre Tariot, Banner Alzheimer\u2019s Institute, Phoenix, AZ (US); and Dr. Juan Fortea, Hospital of Sant Pau, Barcelona (Spain).<\/p>\n<p>Dr. Kaj Blennow, the previous Chairman, is retiring from the CAB. AC Immune thanks Dr. Blennow for his support and invaluable guidance.<\/p>\n<p>\n        <b>About\u00a0AC Immune SA\u00a0<\/b>\n      <\/p>\n<p>AC Immune SA\u00a0is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigen\u00ae and Morphomer\u00ae, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development.\u00a0AC Immune\u00a0has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and &gt;$4.5 billion\u00a0in potential milestone payments plus royalties.<\/p>\n<p>SupraAntigen\u00ae is a registered trademark of\u00a0AC Immune SA\u00a0in the following territories: AU, EU, CH, GB, JP, RU, SG and\u00a0USA. Morphomer\u00ae is a registered trademark of AC Immune SA in CN, CH, EU, GB, JP, KR, NO, RU and SG.<\/p>\n<p>The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.<\/p>\n<p>\n        <b>For further information, please contact:<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:490pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:306.4px;vertical-align: top\">\n            <b>SVP,\u00a0Investor Relations\u00a0&amp; Corporate Communications<\/b><\/p>\n<p>Gary Waanders, Ph.D., MBA<br \/>AC Immune<br \/>Phone: +41 21 345 91 91<br \/>Email:\u00a0<a href=\"mailto:gary.waanders@cimmune.com\" rel=\"nofollow\" target=\"_blank\">gary.waanders@acimmune.com<\/a><\/p>\n<\/td>\n<td style=\"width:346.94px;vertical-align: top\">\n<p>            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306.4px;vertical-align: top\">\n            <b>International Media<\/b><\/p>\n<p>Chris Maggos<br \/>Cohesion Bureau<br \/>Phone: +41 79 367 6254<br \/>Email:\u00a0<a href=\"mailto:chris.maggos@cohesionbureau.com\" rel=\"nofollow\" target=\"_blank\">chris.maggos@cohesionbureau.com<\/a><\/td>\n<td style=\"width:346.94px;vertical-align: top\">\n            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        <b>Forward looking statements<\/b>\n      <\/p>\n<p>This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the\u00a0Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and\u00a0AC Immune\u00a0does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/664cf101-2e19-4d1a-85a0-f4262e8baa33\">20251027__ACIU CAB Chair C Mummery<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/YTc5OGQ1Y2MtMTE4ZS00ZWRlLWE1M2QtMThlZTdiMzhhZGJlLTEwMzc0NDMtMjAyNS0xMC0yOC1lbg==\/tiny\/AC-Immune-SA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalities Includes immunotherapies and small molecule drugs targeting intracellular proteinopathies Leadership in groundbreaking early-stage clinical trials reinforces Company\u2019s competencies Lausanne, Switzerland, October 28, 2025 &#8212; AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia clinical trials, as Chairwoman of its Clinical Advisory Board (CAB). Prof. Mummery leads the cognitive disorders service at the UK\u2019s National Hospital for Neurology and Neurosurgery (NHNN), where she has practiced as a consultant neurologist since 2004. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-900967","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalities Includes immunotherapies and small molecule drugs targeting intracellular proteinopathies Leadership in groundbreaking early-stage clinical trials reinforces Company\u2019s competencies Lausanne, Switzerland, October 28, 2025 &#8212; AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia clinical trials, as Chairwoman of its Clinical Advisory Board (CAB). Prof. Mummery leads the cognitive disorders service at the UK\u2019s National Hospital for Neurology and Neurosurgery (NHNN), where she has practiced as a consultant neurologist since 2004. &hellip; Continue reading &quot;AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-28T11:58:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board\",\"datePublished\":\"2025-10-28T11:58:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/\"},\"wordCount\":961,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/\",\"name\":\"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ==\",\"datePublished\":\"2025-10-28T11:58:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board - Market Newsdesk","og_description":"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalities Includes immunotherapies and small molecule drugs targeting intracellular proteinopathies Leadership in groundbreaking early-stage clinical trials reinforces Company\u2019s competencies Lausanne, Switzerland, October 28, 2025 &#8212; AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia clinical trials, as Chairwoman of its Clinical Advisory Board (CAB). Prof. Mummery leads the cognitive disorders service at the UK\u2019s National Hospital for Neurology and Neurosurgery (NHNN), where she has practiced as a consultant neurologist since 2004. &hellip; Continue reading \"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-28T11:58:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board","datePublished":"2025-10-28T11:58:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/"},"wordCount":961,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/","name":"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ==","datePublished":"2025-10-28T11:58:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNTQwNyM0MDIyNTUyODkjMjAyNTg3MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-appoints-renowned-neurologist-catherine-mummery-as-chair-of-clinical-advisory-board\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=900967"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900967\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=900967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=900967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=900967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}